- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02792036
Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma
Retinoblastoma (RB) is the most common intraocular tumor of childhood. Recurrent or refractory disease following therapy most often occurs due to persistence of vitreous disease and/or retinal reactivation of the main tumor mass. With this treatment protocol, investigators seek to identify a less invasive method of local drug delivery that does not disrupt the eye's integrity.
PRIMARY OBJECTIVE:
- To determine the safety and toxicity profile associated with intravitreal carboplatin for the treatment of recurrent or progressive intraocular retinoblastoma with vitreous seeding.
SECONDARY OBJECTIVES:
- To estimate the ocular salvage rate after treatment with intravitreal carboplatin in patients with recurrent or progressive intraocular retinoblastoma with vitreous seeding.
- To evaluate the effects of intravitreal carboplatin therapy on the histopathology of eyes enucleated for progressive or recalcitrant disease while on therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The eye(s) will be sterilized prior to injection. Aqueous fluid (0.1-0.15ml) will be withdrawn and sent for pathology review. Carboplatin diluted in normal saline will be administered via intravitreal injection under anesthesia once to each eligible eye approximately every 14 days. Following the injection, triple freeze/thaw cryotherapy is applied to the injection site and the eye is washed with water. The eye is gently "shaken" in all directions to evenly distribute the drug.
This trial will use a traditional phase I design for dose de-escalation with two dose levels. The first 6 patients will be enrolled at dose level 1 and will be observed for dose-limiting toxicity (DLT) throughout the treatment period up to approximately 5 months after start of therapy. If 0-2 (of the first 6) participants experience DLT, a second cohort of 6 patients will be enrolled at the same dose level 1. Study accrual would be completed at 12.
However, if 3 or more of the first 6 patients experience DLT at dose level 1, the dose level would be de-escalated to level -1 and 6 patients enrolled at this level (dose -1). If 0-2 patients experience DLT at dose level -1, a second cohort of 6 patients will be enrolled at dose level -1, and the study accrual would be complete. If 3 or more patients experience DLT at dose level -1, accrual would also be complete.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Refractory or recurrent retinoblastoma with vitreous seeding meeting eligibility criteria by ultrasonic biomicroscopy performed during examination under anesthesia (EUA) by an ophthalmologist:
- At least three consecutive clock hours of disease-free, attached peripheral retina through which the intraocular injection may be administered.
- Absence of invasion in anterior and posterior chamber.
- Absence of anterior hyaloid detachment.
- Absence of retinal detachment at the entry site.
- Absence of tumor at the entry site.
- ECOG Performance Score must be ≤ 2 within two weeks prior to registration.
- Participants must have an adequate liver function, as defined by bilirubin ≤3 x upper limit of normal (ULN), and SGOT and SGPT ≤3 x ULN.
- Participants must have adequate renal function as defined by serum creatinine ≤3 x ULN for age.
- Legal guardians must sign an informed consent indicating that they are aware of this study, the possible benefits, and toxic side effects. Legal guardians will be given a signed copy of the consent form.
Exclusion Criteria:
- Presence of metastatic disease or gross orbital involvement.
- Participants must not have an invasive infection at time of protocol entry.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Participants with retinoblastoma that is refractory or has relapsed inside the eye. Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy. |
Carboplatin will be given intravitreally.
Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response.
An injection of consolidation will be given once a complete response is observed.
If further regression of "stable" seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team.
Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye).
Other Names:
Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only.
It will be given for continued use for five days following the carboplatin injection to prevent infection.
Other Names:
Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
Other Names:
Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who develop dose-limiting toxicity (DLT)
Time Frame: From baseline through end of therapy (up to 5 months)
|
DLTs are defined as any of the following: uveitis, sterile or infectious endophthalmitis, retinopathy or rhegmatogenous retinal detachment, massive vitreous hemorrhage that obscures direct visualization of the retina/tumor, and/or cataract that threatens the visual axis or view by treating physician. Grade 3 or 4 allergic reactions should lead to discontinuation of intravitreal carboplatin injections. Patients who have grade 3 or 4 allergic reactions will not be evaluable for this objective and will be replaced. |
From baseline through end of therapy (up to 5 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rachel Brennan, MD, St. Jude Children's Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Retinal Diseases
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Eye Diseases, Hereditary
- Eye Neoplasms
- Retinal Neoplasms
- Retinoblastoma
- Antineoplastic Agents
- Carboplatin
Other Study ID Numbers
- iRET
- NCI-2016-00848 (Registry Identifier: NCI Clinical Trial Registration Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinoblastoma
-
Children's Oncology GroupRecruitingBilateral Retinoblastoma | Childhood Intraocular Retinoblastoma | Unilateral Retinoblastoma | Group D Retinoblastoma | Stage I RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular Retinoblastoma | Recurrent Retinoblastoma | Extraocular RetinoblastomaUnited States, Canada, Puerto Rico
-
Children's Hospital Los AngelesRecruitingRetinoblastoma | Retinoblastoma Bilateral | Retinoblastoma UnilateralUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingCancer Survivor | Retinoblastoma | Unilateral Retinoblastoma | Intraocular Retinoblastoma | Biological SiblingUnited States, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingRetinoblastoma | Pediatric RetinoblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedIntraocular RetinoblastomaUnited States, Canada, Australia, New Zealand, India
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
Amsterdam UMC, location VUmcRecruitingRetinoblastoma | Trilateral RetinoblastomaNetherlands
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoActive, not recruitingUnilateral RetinoblastomaArgentina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnilateral RetinoblastomaUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
AkesoRecruitingAdvanced Squamous Non Small Cell Lung CancerChina
-
Barts & The London NHS TrustUniversity College London HospitalsCompletedMetastatic SeminomaUnited Kingdom
-
North Bristol NHS TrustWithdrawnGlioblastoma MultiformeUnited Kingdom